Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Emtricitabine Stories

2014-04-15 04:20:50

LONDON, April 15, 2014 /PRNewswire/ -- reViral, an antiviral drug discovery and development company, focused on diseases caused by the respiratory syncytial virus (RSV), today announced the appointment of Professor Raymond Schinazi to its Board as a Non-Executive Director, effective from 9 April 2014. Professor Schinazi has had a long and prestigious career in the industry having founded several successful biotechnology companies including Pharmasset, where he chaired...

2014-03-24 08:27:25

Data to be presented in April at the European Association for the Study of the Liver Meeting CARLSBAD, Calif., March 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that treatment with an antisense compound targeting hepatitis B virus (HBV) produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of HBV infection. These data will be presented at the 49(th) annual meeting of the European...

2014-01-31 00:21:48

PITTSBURGH and MUMBAI, India, Jan. 31, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its India-based subsidiary Mylan Pharmaceuticals Private Limited has been named Gilead Sciences, Inc.'s (Nasdaq: GILD) exclusive branded medicines business partner for India. Under the agreement, Mylan will market and distribute in India Gilead's: -- HIV therapies Viread(® )(tenofovir disoproxil fumarate), Truvada(®) (emtricitabine/tenofovir disoproxil fumarate) and the...

2013-12-04 12:23:25

The Strongest Dynamic Decreasing Sales in the HIV Market is Generic Erosion of Key Antiretroviral Drugs, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that major-market sales of antiretroviral (ARV) drugs for HIV will decrease marginally over the next decade, from an estimated $13.4 billion in 2012 to $13.1...

2013-04-29 11:36:57

A novel drug developed by Gilead Sciences and tested in an animal model at the Texas Biomedical Research Institute in San Antonio suppresses hepatitis B virus infection by stimulating the immune system and inducing loss of infected cells. In a study conducted at Texas Biomed's Southwest National Primate Research Center, researchers found that the immune modulator GS-9620, which targets a receptor on immune cells, reduced both the virus levels and the number of infected liver cells in...

Billions Saved With Generic HIV Medication
2013-01-15 18:45:18

Lee Rannals for redOrbit.com — Your Universe Online Replacing brand-name, antiretroviral drugs recommended for control of HIV infection with generic medications could save nearly $1 billion a year on health care costs in the US. This strategy of replacing the brand-name drugs with the soon-to-be-available generic drugs could also come with its risks, diminishing the efficacy of the HIV treatment. "The switch from branded to generic antiretrovirals would place us in the...

2012-12-10 16:24:00

TITUSVILLE, N.J., Dec. 10, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT(®) (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT(®) for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults....

2012-08-02 06:24:36

PITTSBURGH and HYDERABAD, India, Aug. 2, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the establishment of a new agreement between its subsidiary Mylan Laboratories Limited and Gilead Sciences Inc. Under this agreement, Mylan has licensed the rights to produce and market generic versions of Gilead HIV/AIDS therapies containing Emtricitabine, including single and fixed-dose combinations. Emtricitabine is marketed by Gilead under the brand name Emtriva(®), and a fixed-dose...

2012-07-19 12:09:34

Safety, tolerability study to enroll MSM in the United States and Puerto Rico Scientists are launching the first clinical trial to test whether drug regimens containing maraviroc, a medication currently approved to treat HIV infection, are also safe and tolerable when taken once daily by HIV-uninfected individuals at increased risk for acquiring HIV infection. The eventual goal is to see if the drug regimens can reduce the risk of infection. The trial involves a strategy known as...

AIDS Drug Could Get Approved This Summer
2012-06-30 06:29:18

redOrbit Staff & Wire Reports - Your Universe Online The fight against AIDS could get some help this summer, as the Food and Drug Administration (FDA) is expected to approve a drug used to prevent the transmission of HIV, the AIDS virus. Made by Gilead Sciences of Foster City, California, Truvada is already widely used in combination with other drugs to treat patients with HIV. To help the approval process, 2 studies have been published in The Lancet which show just how effective...